Pharmacyclics-Janssen's ibrutinib wins third breakthrough status

04/9/2013 | Fox Business · RTT News

The FDA granted a third breakthrough therapy designation to Pharmacyclics and Janssen Biotech's experimental oral agent ibrutinib as a treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma with deletion of the short arm of chromosome 17. The designation was based on positive data from preclinical and clinical trials.

View Full Article in:

Fox Business · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ
RN Care Manager
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC